{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/721-US20210060002A1(Pending) not sealed.pdf"}, "page_content": "[ 0084 ] The inventors further tested three analogues of\n\nE6 berbamine\n\nberbamine including isotetrandrine , fangchinoline , and E6\n\nberbamine to see if they have anti - infection effect against the\n\n[ 0085 ] As shown in FIGS . 4A to 4C , it was found that\n\nflavivirus particularly JEV and ZIKV .\n\nisotetrandrine significantly inhibited both JEV and ZIKV\n\ninfections of host cells . Referring to FIG . 7C , the EC50 of\n\nisotetrandrine against JEV in A549 cells is around 12 uM .\n\n[ 0086 ] As shown in FIGS . 5A to 5C , it was found that\n\nfangchinoline significantly inhibited both JEV and ZIKV\n\ninfections of host cells . Referring to FIG . 8C , the EC50 of\n\nfangchinoline against JEV in A549 cells is around 11 uM .\n\n[ 0087 ] As shown in FIG . 6A , it was found that E6 - ber\n\nbamme markedly inhibited the infection of JEV or ZIKV , as\n\n111H\n\nmanifested by strong inhibition of JEV - NSI and ZIKV\n\nN\n\nEnvelope protein expression in host cells treated with\n\nE6 - berbamine .\n\n[ 0088 ] Moreover , the inventors determined their effect\n\nagainst JEV or ZIKV infection in another host cell line to\n\nensure their anti - viral effects are not cell type specific .\n\nReferring to FIG . 6B , treatment of JEG - 3 cells with ber\n\nbamine , isotetrandrine , fangchinoline , and E6 berbamine all\n\nsignificantly inhibited JEV or ZIKV infection as shown by\n\nIsotetrandrine\n\nDsRNA immunostaining followed by high - content image\n\nUS 2021/0060002 A1\n\nMar. 4, 2021\n\n-continued", "type": "Document"}}